Your browser doesn't support javascript.
loading
Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia.
Takao, S; Chien, W; Madan, V; Lin, D-C; Ding, L-W; Sun, Q-Y; Mayakonda, A; Sudo, M; Xu, L; Chen, Y; Jiang, Y-Y; Gery, S; Lill, M; Park, E; Senapedis, W; Baloglu, E; Müschen, M; Koeffler, H P.
Afiliación
  • Takao S; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Chien W; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Madan V; Cedars-Sinai Medical Center, Division of Hematology/Oncology, University of California Los Angeles, School of Medicine, Los Angeles, CA, USA.
  • Lin DC; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Ding LW; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Sun QY; Cedars-Sinai Medical Center, Division of Hematology/Oncology, University of California Los Angeles, School of Medicine, Los Angeles, CA, USA.
  • Mayakonda A; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Sudo M; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Xu L; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Chen Y; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Jiang YY; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Gery S; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Lill M; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Park E; Cedars-Sinai Medical Center, Division of Hematology/Oncology, University of California Los Angeles, School of Medicine, Los Angeles, CA, USA.
  • Senapedis W; Cedars-Sinai Medical Center, Division of Hematology/Oncology, University of California Los Angeles, School of Medicine, Los Angeles, CA, USA.
  • Baloglu E; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Müschen M; Karyopharm Therapeutics, Newton, MA, USA.
  • Koeffler HP; Karyopharm Therapeutics, Newton, MA, USA.
Leukemia ; 32(3): 616-625, 2018 03.
Article en En | MEDLINE | ID: mdl-28904384
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_leukemia Asunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / NAD Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Singapur
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_leukemia Asunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / NAD Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Singapur